Tratamiento antifúngico con posaconazol y anfotericina B en paciente con mucormicosis rinosinusal

Tratamiento antifúngico con posaconazol y anfotericina B en paciente con mucormicosis rinosinusal

Show other versions (1)

Introducción: La mucormicosis es una infección fúngica con elevada morbilidad y mortalidad. Se requiere tanto tratamiento quirúrgico como antifúngico, siendo el antimicótico de elección anfotericina B. Posaconazol es un antimicótico derivado de triazol que presenta actividad in vitro e in vivo fren...

Full description

Bibliographic Details
Main Authors:	MT Martínez-Lazcano, P. Herraiz Robles, M. Bonete Sánchez, L. Pons Martínez, SI Ruiz Darbonnéns
Format:	Article
Language:	English
Published:	Fundación Pharmaceutical Care España 2015-04-01
Series:	Pharmaceutical Care España
Subjects:	mucormicosis anfotericina B liposomal posaconazol terapia rescate.
Online Access:	https://www.pharmcareesp.com/index.php/PharmaCARE/article/view/228

Similar Items

Tratamiento antifúngico con posaconazol y anfotericina B en paciente con mucormicosis rinosinusal
by: MT Martínez-Lazcano, et al.
Published: (2015-04-01)

Oxigenoterapia hiperbárica como tratamiento complementario en mucormicosis asociada a COVID-19: a propósito de dos casos
by: Víctor Valencia-Caballero, et al.
Published: (2023-03-01)

Mucormicosis cerebral
by: Edgard Eliud Castillo Tamara, et al.
Published: (2021-05-01)

Mucormicosis diseminada en un paciente diabético: un reporte de caso
by: Natalia Vargas Herrera, et al.
Published: (2019-12-01)

Síndrome hemofagocítico por mucormicosis en paciente pediátrico inmunocompetente. Reporte de caso
by: Gloria Celeste Samudio-Domínguez
Published: (2023-10-01)

Mucormicosis rinocerebral en paciente con cefalea y diabetes mellitus Rhinocerebral mucormycosis in diabetic patient with headache
by: Juan Camilo Botero, et al.
Published: (2008-03-01)

Tratamento da forma mucosa de leishmaniose sem resposta a glucantime, com anfotericina B liposomal
by: Raimunda Nonata Ribeiro Sampaio, et al.
Published: (1997-04-01)

Mucormicosis pulmonar no asociada a inmunodepresión en paciente pediátrico. Caso clínico
by: Rosa Pantoja Revelo, et al.
Published: (2022-12-01)

Uso de anfotericina B liposomal en leishmaniasis cutánea diseminada causada por Leishmania braziliensis en un paciente pediátrico con síndrome de Down
by: Aidé Sandoval-Juárez, et al.
Published: (2023-03-01)

Anfotericina B: uma revisão sobre suas diferentes formulações, efeitos adversos e toxicidade
by: Diego Rodrigues Falci, et al.
Published: (2015-07-01)

Mucormicosis oral asociada a COVID-19 y diabetes mellitus: descripción de un caso
by: Julio César Velasco, et al.
Published: (2024-03-01)

Efficacy of combination therapy of amphotericin and posaconazole in treatment of mucormycosis
by: Sridhara S, et al.
Published: (2023-03-01)

RACIONALIZAÇÃO DO USO DE ANFOTERICINA B LIPOSSOMAL EM UM HOSPITAL TERCIÁRIO EM RECIFE
by: Martha Maria Romeiro Figueiroa Ferreira Fonseca, et al.
Published: (2023-10-01)

Posaconazole-induced Glucocorticoid Deficiency in a Patient with Myelodysplastic syndrome.
by: Antonia Precali, et al.
Published: (2023-01-01)

Posaconazole as single or adjunctive antifungal in mucormycosis of the maxilla: systematic review and meta-analysis
by: Pardiwala Arwa, et al.
Published: (2023-01-01)

Determination of Posaconazole in Plasma/Serum by High-Performance Liquid Chromatography with Fluorescence Detection
by: Peter H. Tang
Published: (2017-05-01)

Mucurmicosis rinocerebral en un paciente con diabetes descompensada
by: Dora Montiel Jarolin, et al.
Published: (2023-01-01)

Primary pulmonary mucormycosis associated with plasma cell myeloma
by: Carmen Patricia Alfonso González, et al.
Published: (2013-04-01)

Mucormicosis cutánea en un recién nacido pretérmino: A propósito de un caso
by: Calabria O Betty, et al.
Published: (2005-12-01)

The Impact of Hypromellose on Pharmaceutical Properties of Alginate Microparticles as Novel Drug Carriers for Posaconazole
by: Katarzyna Kruk, et al.
Published: (2023-06-01)

Intravenous posaconazole: key features of clinical pharmacology and practical applications
by: A. V. Veselov, et al.
Published: (2022-04-01)

Severe Posaconazole-Induced Glucocorticoid Deficiency with Concurrent Pseudohyperaldosteronism: An Unfortunate Two-for-One Special
by: Alejandro Villar-Prados, et al.
Published: (2021-07-01)

A Review of Population Pharmacokinetic Models of Posaconazole
by: Ding Q, et al.
Published: (2022-10-01)

Formation and Characterisation of Posaconazole Hydrate Form
by: Michail Lykouras, et al.
Published: (2022-12-01)

External evaluation of published population pharmacokinetic models of posaconazole
by: Shuqi Huang, et al.
Published: (2022-09-01)

Rescate medular con filgrastim y ácido folínico en intoxicación por metotrexato
by: Marlon Villacís Aveiga, et al.
Published: (2019-04-01)

Polyelectrolyte-Complex-Based Hydrogel Inserts for Vaginal Delivery of Posaconazole and Probiotics
by: Sanjeevani Deshkar, et al.
Published: (2023-10-01)

Sample Preparation of Posaconazole Oral Suspensions for Identification of the Crystal Form of the Active Pharmaceutical Ingredient
by: Michail Lykouras, et al.
Published: (2020-12-01)

Mucormycosis and aspergillosis: The deadly duo in COVID-19—a case report
by: Bijaya Mohanty, et al.
Published: (2022-01-01)

Posaconazole: An Update of Its Clinical Use
by: Simon Leung, et al.
Published: (2015-10-01)

Synergistic effect of pyrvinium pamoate and posaconazole against Cryptococcus neoformans in vitro and in vivo
by: Yali Li, et al.
Published: (2022-12-01)

THE EFFICACY OF POSACONAZOLE FOR PROPHYLAXIS OF INVASIVE MYCOSES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
by: G. A. Klyasova, et al.
Published: (2017-11-01)

Mucoadhesive Alginate/Pectin Films Crosslinked by Calcium Carbonate as Carriers of a Model Antifungal Drug—Posaconazole
by: Marta Szekalska, et al.
Published: (2023-10-01)

Evaluation of Posaconazole for Primary Prophylaxis of IFI in Acute Myeloid Leukemia under Intensive Induction Chemotherapy. Comparative Real Life Study with Fluconazole in two Hematological Centers in Algeri
by: Mohamed Amine Bekadja, et al.
Published: (2021-12-01)

Utilization of nanotechnology and experimental design in the development and optimization of a posaconazole‒calendula oil nanoemulgel for the treatment of mouth disorders
by: Mohammed Alissa, et al.
Published: (2024-02-01)

The Outcome of Antifungal Prophylaxis with Posaconazole in Patients with Acute Myeloid Leukemia: A Single-Center Study
by: Vildan Özkocaman, et al.
Published: (2018-11-01)

Mucormycosis in a Severe Trauma Patient Treated with a Combination of Systemic Posaconazole and Topical Amphotericin B—Case Report
by: Filip Keller, et al.
Published: (2023-09-01)

Comparative pharmacoeconomic analysis of posaconazole therapy in tablet form and in suspension for invasive fungal infections prevention
by: I. S. Krysanov, et al.
Published: (2021-06-01)

Pharmacokinetics of Venetoclax Co-Administered with Posaconazole in Patients with Acute Myeloid Leukemia
by: Simona De Gregori, et al.
Published: (2023-06-01)

Reavaliação da suscetibilidade de Candida à anfotericina B: estudo comparativo com isolados de três hospitais do estado do Rio Grande do Sul Reevaluation of Candida susceptibility to amphotericin B: comparative study using isolates from three hospitals in the state of Rio Grande do Sul
by: Everton Boff, et al.
Published: (2008-02-01)